Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2006-10-03
2006-10-03
Price, Elvis O. (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C560S008000, C560S009000, C560S019000, C560S070000, C206S569000
Reexamination Certificate
active
07115766
ABSTRACT:
Radiolabeled fluorinated compounds useful for imaging in the diagnosis of Parkinson's Disease are disclosed. Methods and kits for their synthesis are also disclosed.
REFERENCES:
patent: 4762881 (1988-08-01), Kauer
“No-Carrier-Added (NCA) ARYL [18F] Fluorides Via the Nucleophilic Aromatic Substitution of Electron-Rich Aromatic Rings,” Ding et al.Journal of Fluorine Chemistryvol. 48, pp. 189-205 (1990).
“Synthesis of 18F Labelled Fluoro-m-tyrosine, Fluoro-m-tyramine and Fluoro-3-hydroxyphenylacetic Acid,” Raman Chirakal, Gary J. Schrobilgen, Gunter Fimau and Stephen Gamett, Appl. Radiat. Isot. 1991 42, No. 2, 113-119.
“Synthesis of Radiofluorinated Analogs of m-Tyrosine as Potential L-Dopa Tracers via Direct Reaction with Acetylhypofluorite,” OT DeJesus et al., Appl. Radiat. Isot. vol. 41, No. 5, pp. 433-437, 1990.
Enzymatic synthesis of no-carrier-added 6-[18F]fluoro-L-dopa with β-tyrosinase, SciFinder Scholar, Nov. 19, 2000, p. 3 (Abstract).
“The Synthesis of 6-[18F] Fluoro-L-Dopa by Chiral Catalytic Phase-Transfer Alkylation,” C. Lemaire et al., J. Label Labelled Cpd., Radiopharm 42 (1999) S113-S115.
“Monograph series on aging-related diseases: XII,” N. Kontakos and J. Stokes, Chronic Dis. Can. 1999 20, 58-76 (Abstract).
“Asymmetric Synthesis of 6-{18F] Fluoro-L-Dopa Using a Chiral Nickel Complex of the Schiff Base of (s)-O-[(N-Benzylprolyl)-Amino] Benzophenone and Glycine,” r. n. Krasikova, et al., J. Label Labelled Cpd., Radiopharm. 1999, 42, 512-5104.
“Enantioselective Synthesis of 6-[Fluorine-18]-Fluoro-L-Dopa from No-Carrier-Added Fluorine-18-Fluoride,” Christian Lemaire, et al., The Journal of Nuclear Medicine, 1994, 35, 1996-2002.
“No-Carrier-Added (NCA) Aryl [18F] Fluorides via the Nucleophilic Aromatic Substitution of Electron-rich Aromatic Rings,”Y.S. Ding, et al., Journal of Fluorine Chemistry, 48 (1990) 189-205.
“Dopamine visualized in the basal ganglia of living man,” E.S. Garnett, et al., Nature Sep., 1983, 305, 137-138.
“Parkinson's Disease and the U.S. Health Care System,” Pamela P. Fischer, RN,BSN, Journal of Community Health Nursing, 1999 l6(3), 191-204.
“The Natural History of Parkinson's Disease,” W.H. Poewe, MD et al., American Neurological Association, 1998, pp. S1-S9.
“PET studies of functional compensation in a primate model of Parkinson's disease,” JL. Eberling, et al., Neuroreport. 8(12):2727-33, Aug. 18, 1997 (Abstract).
“Understanding Parkinson's Disease,” Moussa B. H. Youdim, et al., Scientific American, Jan. 1997, pp. 52-59.
“Synthesis of 6-[18F] and 4-[18F]fluoro-L-m-tyrosines via regioselective radiofluorodestannylation,” SciFinder Scholar, Jan. 29, 2000 (Abstract).
“Asymmetric synthesis of fluorinated L-tyrosine and meta-L-tyrosines,” Michel Monclus, et al., Journal of Fluorine Chemistry, 70j (1995) 39-43.
“Positron emission tomography for evaluation of dopaminergic function using a neurotransmitter analog L-18F-m-tyrosine in monkey brain,” SciFinder Scholar, Jan. 29, 2000 (Abstract).
“The noncatechol tracer 6-fluoro-m-tyrosine: Extrastriatal distribution of dopaminergic function,” SciFinder Scholar, Jan. 29, 2000 (Abstract).
“Radioflurinated L-m-Tyrosines: New In-Vivo Probes for Central Dopamine Biochemistry,” Jorge R. Barrio, et al., Journal of Cerebral Blood Flow and Metabolism, 16:667-678.
“6-[18F] Fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates,” Shaun Jordan, et al., Elsevier Science B.V., Brain Research 750 (1997) 264-276.
“Evaluation of Fluorinated m-Tyrosine Analogs as PET Imaging Agents of Dopamine Nerve Terminals: Comparision with 6-Fluorodopa,” Onofre T. DeJesus, et al., The Journal of Nuclear Medicine, vol. 38, No. 4, Apr. 1997.
“Affinites of Dopamine Analogs for Monoamine Granular and Plasma Membrane Transporters: Implicationos for PET Dopamine Studies,” Christopher J. Endres, et al., Life Sciences, vol. 60, No. 26, pp. 2399-2406, 1997.
“A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes,” Jamie L. Eberlind, et al., Elsevier Science B.V., Brain Research 805 (1998) 259-262.
“An In Vivo Microdialysis Study of Striatal 6-[18F] Flluoro-L-m-Tyrosine Metabolism,” Shaun Jordan, et al. Neurochemical Research, vol. 23, No. 4, 1998, pp. 513-517.
“Evaluation of Dopaminergic Presynaptic Integrity: 6-[18F] Fluoro-L-Dopa Versus 6-{18F] Fluoro-L-m-Tyrosine, DJ Doudet, et al., Journal of Cerebral Blood Flow and Metabolism, 19:278-287.
“Localization of Trapping of 6-[18F] fluoro-L-m-tyrosine, an Aromatic L-Amino Acid Decarboxylase Tracer for PET,” W. Douglas Brown, et al., SYNAPSE 34:111-123 (1999).
“Dopamine transporter loss and clinical changes in MPTP-lesioned primates,” Jamie L. Eberling, Elsevier Science B.V., Brain Research 832 (1999) 184-187.
Evaluation of [F-18] Fluoro-m-tyrosine (FMT) Patient Studies; dosimetry and statistical considerations, T.E. Nordahl, et al., The Journal of Nuclear Medicine, vol. 39, No. 5, May 1998 Supplement, p. 190.
“Intracranial Hypotension with Parkinsonism, Ataxia, and Bulbar Weakness,” S.I. Anthony, et al., Arch Neurol vol. 56, Jul. 1999, p. 869-872.
“The time course of metabolites in human plasma after 6-[18F] fluoro-L-m-tyrosine administration,” Linda M. Wahl, European Journal of Nuclear Medicine, vol. 26, No. 11, Nov. 1999, pp. 1407-1412.
“Regions of Interest in the Venous Sinuses as Input Functions for Quantitative PET,” Lindi M. Wahl, The Journal of Nuclear Medicine, vol. 40, No. 10, Oct. 1999.
“PET and Drug Research and Development,” Joanna S. Fowler, et al., The Journal of Nuclear Medicine, vol. 40, No. 7, Jul. 1999, pp. 1154-1163.
“Imaging the functioning human brain,” Xuchu Weng, et al., Proc. Natl. Acad. Sci. USA, vol. 96, pp. 11073-11074, Sep. 1999.
F-18 labeled biomolecules for PET studies in the neurosciences, Ding YS, Journal of Fluorine Chemistry, 101: (2) 291-295 Feb. 2000 (Abstract).
“Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-D-glucose,” M. Reivich, et al., Acta Neurol. Scand. 1977 56 (Suppl 64), pp. 190-191.
“Radiopharmaceuticals XXVII. 18F-Labeled 2-deoxy-2-fluoro-d-glucose as a Radiopharmaceutical for Measuring Regional Myocardinal Glucose Metabolism in vivo: Tissue Distribution and Imaging Studies in Animals.,” BM Gallagher, Journal Nuclear Medicine, 1977, 18, 990-996.
“Synthesis of No-Carrier-Added Fluorine-18 2-fluoro-2-deoxy-d-glucose,” Timothy J. Tewson, Journal Nucl Med. 24: 718-721, 1983.
“Efficient Stereospecific Synthesis of No-Carrier-Added 2-[18F]-Fluoro-2-Deoxy-D-Glucose Using Aminopolyether Supported Nucleophilic Substitution,” K. Hamacher, et al., J Nucl Med 27:235-238, 1986.
“Neurochemical Imaging of Alzheimer's Disease and Other Degenerative Dementias,” KA Frey, et al., J. Nuclear Med. 1998, 42, 166-178 (Abstract).
“Positron emission tomography with 18-F-fluorodeoxyglucose in the staging and follow-up of lymphoma: status quo and quo vadis,” M. Bangerter, Onkologie Oct. 1999, 22, 382-386 (Abstract).
Metals Suitable for Fluorine Gas Target Bodies: First Use of Al;uminum for the Production of [18F]F2, Allyson Bishop, et al., Nuclear Med. Biol. 1996, 23, 181-188.
Proton Irradiation of [180]02: Production of [18F]F2 and [18F]F2+[18F]OF2, Allyson Bishop et al., Nuclear Med. Biol. 1996, 23, 189-199.
“The Stereoselective Synthesis of Alpha-Amino-Acids by Phase-Transfer Catalysis,” Martin J. O'Donnell, J. Am. Chem. Soc. 1989, 111, 2353-2355.
“A New Active Catalyst Species for Enantioselective Aklylation by Phase-Transfer Catalysis,” Martin J. O'Donnell, et al., Tetrahedron 1994, 50,
Chin Frederick T.
Delgado Francisca
Mulholland G. Keith
O'Donnell Martin J.
Barnes & Thornburg LLP
Indiana University Research & Technology Corp.
Price Elvis O.
LandOfFree
Nucleophilic approach for preparing radiolabeled imaging... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleophilic approach for preparing radiolabeled imaging..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleophilic approach for preparing radiolabeled imaging... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631684